Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific announces amended agreement to settle Guidant product lawsuits

Boston Scientific : 19 November, 2007  (New Product)
Boston Scientific has announced that an amended agreement has been reached to settle claims associated with a series of product communications issued by Guidant in 2005 and 2006.
Boston Scientific acquired Guidant last year. This agreement amends a prior agreement Boston Scientific reached in July 2007 to cover additional unanticipated claims.

The amended agreement was reached during mediation sessions conducted before US Magistrate Judge Arthur J Boylan in Minneapolis, USA.

Under the terms of the amended agreement, subject to certain conditions,
Boston Scientific will pay a total of up to $240 million. The agreement covers 8,550 patient claims, including all of those that have been consolidated in the US District Court for the District of Minnesota in a Multi-District Litigation (MDL), as well as other filed and unfiled claims throughout the USA. As a result of the amendment, proceedings in Minnesota state court have - like the trials in the bellwether cases in the MDL - been stayed.

Under the terms of the prior agreement, Boston Scientific had agreed to pay
$195 million to settle over 4,000 claims in the MDL, as well as an undetermined number of additional similar claims. The company believes that the claims covered by the amended agreement constitute substantially all currently asserted claims in the USA arising from the 2005 and 2006 product communications.

'We are pleased with this amendment, which is in the best interest of all
involved,' said Jim Tobin, president and chief executive officer of Boston
Scientific.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo